HERTHENA-Lung01: A Randomized Phase 2 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Previously Treated Metastatic EGFR-mutated NSCLC-MedSci.cn

HERTHENA-Lung01: A Randomized Phase 2 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Previously Treated Metastatic EGFR-mutated NSCLC

Janne, P; Johnson, M; Goto, Y; Yang, JC; Karam, S; Chen, S; Qiu, Y; Yu, H; Yu, C

JOURNAL OF THORACIC ONCOLOGY, 2021; 16 (3): S236

科室
- - 订阅+
  - 更多科室
工具
服务